News & Updates

Use of glucagon-like peptide-1 receptor agonists (GLP-1RA) among patients with type 2 diabetes (T2D) appears to have protective benefits against the development of glaucoma compared with exposure to other second-line antihyperglycaemic medications, according to a study.

Another feather may have been added in the cap of glucagon-like protein-1 receptor agonists (GLP-1 RAs) – the class of type 2 diabetes (T2D) drugs that has become a blockbuster recently due to their remarkable weight loss benefit – as evidence of their potential to reduce the risk of obesity-associated cancers (OACs) comes to light.

Treatment with canagliflozin results in clinically meaningful reductions in glycated haemoglobin (HbA1c), when compared with placebo, in children and adolescents with type 2 diabetes (T2D), as shown by the results of a phase III study presented at EASD 2024.

Adding sodium–glucose co-transporter-2 (SGLT2) inhibitors to usual care in the treatment of hospitalized patients with COVID-19 does not necessarily lead to improved survival, according to the results of a meta-analysis.

In the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), the use of enzalutamide yields small improvements in outcomes when compared with abiraterone acetate, according to a retrospective study.